- Tetra Bio-Pharma Inc. (TBP) has shared positive preclinical results from live COVID-19 infection studies and a septic lung model
- The studies observed ARDS-003 and its potential to increase COVID-19 survival rates
- ARDS-003 contains a potent substance from a type two cannabinoid receptor
- The drug can decrease hyperinflammatory responses and slow disease progression
- Tetra also developed an oral formulation of the drug that can work with other treatments
- Tetra Bio-Pharma Inc. (TBP) is up 7.69 per cent trading at $0.07 per share as of 1:14 p.m. ET.
Cannabis-derived drug developer, Tetra Bio-Pharma Inc. (TBP), shared positive preclinical results from live COVID-19 infection studies and a septic lung model.
The company stated these independently researched studies observed ARDS-003 and its potential to increase survival rates following a COVID-19 infection in a “humanized” mouse model.
According to the company, ARDS-003 is a new drug which contains, a potent substance from a type two cannabinoid receptor, onternabez, which is an important immune system target.
Tetra stated ARDS-003 can help regulate acute systemic inflammation and prevent sepsis, lung dysfunction, and organ damage. Allegedly, the studies demonstrated that ARDS-003 decreases hyperinflammatory response and slows disease progression.
On top of this, Tetra shared that when using a recent septic lung model ARDS-003 produced a significant reduction of systemic cytokine and chemokine release. Lung tissue was improved, peripheral immune hyperactivation was reduced, and there was an improvement in capillary perfusion in lung tissue compared to controls.
The company’s research team has also developed an oral formulation of the drug for an immediate release that can be used over time and may work well alongside other treatements.
“ARDS-003, for example, could be used as an adjunct to Paxlovid or other antivirals to help reduce the morbidities associated with prolonged infection… In the case of COVID, the treatment period with ARDS-003 could be extended to continue to improve clinical outcome and prevent the rebound effect observed in immunocompromised patients receiving existing antivirals,” Guy Chamberland, CEO and CRO of Tetra, said.
Tetra Bio-Pharma Inc. (TBP) is up 7.69 per cent trading at $0.07 per share as of 1:14 p.m. ET.
